107 related articles for article (PubMed ID: 10803532)
41. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
42. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
[TBL] [Abstract][Full Text] [Related]
43. The role of FLT3 in haematopoietic malignancies.
Stirewalt DL; Radich JP
Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
[TBL] [Abstract][Full Text] [Related]
44. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.
Rosnet O; Schiff C; Pébusque MJ; Marchetto S; Tonnelle C; Toiron Y; Birg F; Birnbaum D
Blood; 1993 Aug; 82(4):1110-9. PubMed ID: 8394751
[TBL] [Abstract][Full Text] [Related]
45. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
46. Expression and signal transduction of the FLT3 tyrosine kinase receptor.
Rosnet O; Bühring HJ; deLapeyrière O; Beslu N; Lavagna C; Marchetto S; Rappold I; Drexler HG; Birg F; Rottapel R; Hannum C; Dubreuil P; Birnbaum D
Acta Haematol; 1996; 95(3-4):218-23. PubMed ID: 8677746
[TBL] [Abstract][Full Text] [Related]
47. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
48. [Internal tandem duplication in the juxtamembrane domain of the Flt3 gene found in leukemias].
Yokota S; Kiyoi H
Rinsho Ketsueki; 1998 Feb; 39(2):83-5. PubMed ID: 9545804
[No Abstract] [Full Text] [Related]
49. High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells.
Ishii E; Zaitsu M; Ihara K; Hara T; Miyazaki S
Pediatr Hematol Oncol; 1999; 16(5):437-41. PubMed ID: 10505320
[TBL] [Abstract][Full Text] [Related]
50. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T
Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190
[TBL] [Abstract][Full Text] [Related]
51. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
[TBL] [Abstract][Full Text] [Related]
52. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12-->q13.
Carow CE; Kim E; Hawkins AL; Webb HD; Griffin CA; Jabs EW; Civin CI; Small D
Cytogenet Cell Genet; 1995; 70(3-4):255-7. PubMed ID: 7789184
[TBL] [Abstract][Full Text] [Related]
53. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
54. A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia.
Matsuno N; Nanri T; Kawakita T; Mitsuya H; Asou N
Leukemia; 2005 Mar; 19(3):480-1. PubMed ID: 15625552
[No Abstract] [Full Text] [Related]
55. Hematopoietic receptors of class III receptor-type tyrosine kinases.
Rosnet O; Birnbaum D
Crit Rev Oncog; 1993; 4(6):595-613. PubMed ID: 7506935
[TBL] [Abstract][Full Text] [Related]
56. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
Kiyoi H; Towatari M; Yokota S; Hamaguchi M; Ohno R; Saito H; Naoe T
Leukemia; 1998 Sep; 12(9):1333-7. PubMed ID: 9737679
[TBL] [Abstract][Full Text] [Related]
57. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
[TBL] [Abstract][Full Text] [Related]
58. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
Boissel N; Cayuela JM; Preudhomme C; Thomas X; Grardel N; Fund X; Tigaud I; Raffoux E; Rousselot P; Sigaux F; Degos L; Castaigne S; Fenaux P; Dombret H
Leukemia; 2002 Sep; 16(9):1699-704. PubMed ID: 12200684
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.
Scholl S; Loncarevic IF; Krause C; Kunert C; Clement JH; Höffken K
Leuk Res; 2005 Jul; 29(7):849-53. PubMed ID: 15921740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
